Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer

Frontiers in Oncology

Volumn 2 AUG, Issue , 2012, Pages

  Parthan, Anju ^a   Pruttivarasin, Narin ^a   Davies, Diane ^b   Taylor, Douglas C A ^a   Pawar, Vivek ^c   Bijlani, Akash ^b   Lich, Kristen Hassmiller ^d   Chen, Ronald C ^d  

^a OPTUM   (United States)

^b ACCURAY INCORPORATED   (United States)

^c BAYER CORPORATION   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cancer; Cost effectiveness; Localized; Prostate; Radiation

Indexed keywords

AGED; ARTICLE; BRACHYTHERAPY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIFE EXPECTANCY; MALE; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PROSTATE CANCER; PROTON THERAPY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIATION THERAPY ONCOLOGY GROUP SCALE; RISK; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL; TOXICITY;

EID: 84881551164     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00081     Document Type: Article

References (37)

1. Agency for Healthcare Research and Quality. (2010). Comparative Evaluation of Radiation Treatments for Clinically Localized Prostate Cancer: An Update. Technology Assessment Report ID: CANT1209.
2. Altekruse, S. F., Kosary, C. L., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Ruhl, J., Howlader, N., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M. P., Lewis, D. R., Cronin, K., Chen, H. S., Feuer, E. J., Stinchcomb, D. G., and Edwards, B. K. (eds). (2010). SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute.
3. Aluwini, S., van Rooij, P., Hoogeman, M., Bangma, C., Kirkels, W. J., Incrocci, L., and Kolkman-Deurloo, I. K. (2010). Cyber knife stereotactic radiotherapy as monotherapy for low-to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J. Endourol. 24, 865-869.
4. Boike, T. P., Lotan, R., Cho, L. C., Brindle, J., DeRose, P., Xie, X. J., Yan, J., Foster, R., Pistenmaa, D., Perkins, A., Cooley, S., and Timmerman, R. (2011). Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. J. Clin. Oncol. 29, 2020-2026.
5. Bolzicco, G., Favretto, M. S., Scremin, E., Tambone, C., Tasca, A., and Guglielmi, R. (2010). Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol. Cancer Res. Treat. 9, 473-477.
6. Bureau of Labor Statistics. (2011). Usual Weekly Earnings of Wage and Salary Workers, ed. M. D. Levi (Bureau of Labor Statistics).
7. Chen, R. C., Clark, J. A., and Talcott, J. A. (2009). Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J. Clin. Oncol. 27, 3916-3922.
8. Coen, J. J., Paly, J. J., Niemierko, A., Weyman, E., Rodrigues, A., Shipley, W. U., Zietman, A. L., and Talcott, J. A. (2012). Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82, e201-e209.
9. Cooke, C. E., Wong, W., and Lee, H. (2005). Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. J. Manag. Care Pharm. 11, 674-680.
10. Freeman, D. E., and King, C. R. (2011). Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat. Oncol. 6, 3.
11. Friedland, J. L., Freeman, D. E., Masterson-McGary, M. E., and Spellberg, D. M. (2009). Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol. Cancer Res. Treat. 8, 387-392.
12. Hamner, J., Lawrence, W. F., Anderson, J. P., Kaplan, R. M., and Fryback, D. G. (2006). Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med. Decis. Making 26, 391-400.
13. Jabbari, S., Weinberg, V. K., Kaprealian, T., Hsu, I. C., Ma, L., Chuang, C., Descovich, M., Shiao, S., Shinohara, K., Roach, M. III, and Gottschalk, A. R. (2012). Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int. J. Radiat. Oncol. Biol. Phys. 82, 228-234.
14. Kang, J. K., Cho, C. K., Choi, C. W., Yoo, S., Kim, M. S., Yang, K., Yoo, H., Kim, J. H., Seo, Y. S., Lee, D. H., and Jo, M. (2011). Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 97, 43-48.
15. Katz, A. J., Santoro, M., Ashley, R., Diblasio, F., and Witten, M. (2010). Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 10, 1. doi:10.1186/1471-2490-10-1
16. King, C. R., Brooks, J. D., Gill, H., Pawlicki, T., Cotrutz, C., and Presti, J. C. Jr. (2009). Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 73, 1043-1048.
17. King, C. R., Brooks, J. D., Gill, H., and Presti, J. C. Jr. (2012). Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82, 877-882.
18. Kirichenko, A. V., Ruth, K., Horwitz, E. M., Buyyounouski, M. K., Feigenberg, S. J., Chen, D. Y., and Pollack, A. (2006). Intensity modulated radiation therapy for prostate cancer: preliminary results on treatment morbidity compared to 3-D conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 66, S326.
19. Konski, A., Speier, W., Hanlon, A., Beck, J. R., and Pollack, A. (2007). Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J. Clin. Oncol. 25, 3603-3608.
20. Konski, A., Watkins-Bruner, D., Feigenberg, S., Hanlon, A., Kulkarni, S., Beck, J. R., Horwitz, E. M., and Pollack, A. (2006). Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66, 408-415.
21. Madsen, B. L., His, R. A., Pham, H. T., Fowler, J. F., Esagui, L., and Corman, J. (2007). Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical results. Int. J. Radiat. Oncol. Biol. Phys. 67, 1009-1105.
22. MAG Mutual. (2011). 2011 MAG Mutual Physicians' Fee and Coding Guide. Atlanta: MAG Mutual Healthcare Solutions, Inc., 2010. Print.
23. Martin, A., and Gaya, A. (2010). Stereotactic body radiotherapy: a review. Clin. Oncol. 22, 157-172.
24. National Cancer Institute. (2012). Bethesda, MD: NIH, DHHS. Available at: http://www.cancer.gov/cancertopics/types/prostate [accessed May 24, 2012].
25. Nguyen, P. L., Gu, X., Lipsitz, S. R., Choueiri, T. K., Choi, W. W., Lei, Y., Hoffman, K. E., and Hu, J. C. (2011). Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J. Clin. Oncol. 29, 1517-1524.
26. Ollendorf, D. A., Hayes, J., McMahon, P., Kuba, M., Tramontano, A., and Pearson, S. D. (2008). Brachytherapy & Proton Beam Therapy for Treatment of Clinically-Localized, Low-Risk Prostate Cancer. Boston: Institute for Clinical and Economic Review. [Final appraisal document].
27. Ollendorf, D. A., Hayes, J., McMahon, P., and Pearson, S. D. (2009). Active Surveillance & Radical Prostatetomy for the Management of Low-Risk, Clinically-Localized Prostate Cancer. Boston: Institute for Clinical and Economic Review. [Final appraisal document].
28. Red Book. (2010). Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Reuters (Healthcare) Inc.
29. Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., Mahadevan, A., Klein, E., Kibel, A., Pisters, L. L., Kuban, D., Kaplan, I., Wood, D., Ciezki, J., Shah, N., and Wei, J. T. (2008). Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358, 1250-1261.
30. Schulte, R. W., Slater, J. D., Rossi, C. J. Jr., and Slater, J. M. (2000). Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahlenther. Onkol. 176, 3-8.
31. Slater, J. D., Rossi, C. J. Jr., Yonemoto, L. T., Reyes-Molyneux, N. J., Bush, D. A., Antoine, J. E., Miller, D. W., Teichman, S. L., and Slater, J. M. (1999). Conformal proton therapy for early-stage prostate cancer. Urology 53, 978-984.
32. Slater, J. D., Yonemoto, L. T., Rossi, C. J. Jr., Reyes-Molyneux, N. J., Bush, D. A., Antoine, J. E., Loredo, L. N., Schulte, R. W., Teichman, S. L., and Slater, J. M. (1998). Conformal proton therapy for prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 42, 299-304.
33. Stewart, S. T., Lenert, L., Bhatnagar, V., and Kaplan, R. M. (2005). Utilities for prostate cancer health states in men aged 60 and older. Med. Care 43, 347-355.
34. Townsend, N. C., Huth, B. J., Ding, W., Garber, B., Mooreville, M., Arrigo, S., Lamond, J., and Brady, L. W. (2011). Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am. J. Clin. Oncol. 34, 6-10.
35. Wiegner, E. A., and King, C. R. (2010). Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 78, 442-448.
36. Zelefsky, M. J., Chan, H., Hunt, M., Yamada, Y., Shippy, A. M., and Amols, H. (2006). Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J. Urol. 176(4 Pt 1), 1415-1419.
37. Zelefsky, M. J., Fuks, Z., Hunt, M., Yamada, Y., Marion, C., Ling, C. C., Amols, H., Venkatraman, E. S., and Leibel, S. A. (2002). High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys. 53, 1111-1116.